Boditech Med Inc.
206640.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$212.52B
Close$
$16613.64
76.6% upside
Current Fair Value
76.6% upsideUndervalued by 76.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $212.52 Billion |
|---|---|
| Enterprise Value | $191.89 Billion |
| Dividend Yield | $150.00 (1.53%) |
| Earnings per Share | $1092 |
| Beta | 0.35 |
| Outstanding Shares | 21,734,000 |
Return
| Return on Equity | 10.50% |
|---|---|
| Return on Assets | 8.55% |
| Return on Invested Capital | 6.56% |
Valuation & Multiples
| P/E Ratio | 8 |
|---|---|
| PEG | -1486.69 |
| Price to Sales | 1.17 |
| Price to Book Ratio | 0.78 |
| Enterprise Value to Revenue | 1.1 |
| Enterprise Value to EBIT | 10.65 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
November 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$47.00 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Boditech Med Inc.
601 employees
CEO: Ui-Yeol Choe Founded in 1998 and headquartered in Chuncheon, South Korea, Boditech Med Inc. specializes in the development of in-vitro diagnostic solutions and reagents. The company's diverse product portfolio includes a range of advanced immunoassay...